This project is part of the EDCTP3 programme supported by the European Union
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
This project is part of the EDCTP3 programme supported by the European Union
Annually, over 35 million pregnancies occur in areas of moderate to high malaria transmission, and over 7 million pregnancies are exposed to malaria in the first trimester.
However, first-trimester pregnancies are generally excluded from clinical trials, making newer, effective antimalarials unavailable during this critical time.
Annually
Over
In 2022
The SAFIRE consortium aims to close the existing data and treatment gaps for this group of patients through a Phase 3b adaptive platform trial conducted in highly malarious areas of Kenya, Mali, Burkina Faso, Uganda and the Democratic Republic of Congo.
SAFIRE will evaluate and generate robust evidence on the safety, tolerability and efficacy of registered antimalarials, which will be beneficial for areas where artemether-lumefantrine (AL) is not used, aligning with the World Health Organization’s strategy of deploying diverse first-line treatments to combat antimalarial resistance.
Findings, including those generated through qualitative research, will be integrated into policies and guidelines, ensuring pregnant women can access the best treatment choices for malaria in early pregnancy.
